Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant.

Slides:

Advertisements

Similar presentations

Fig 2.1B: Axial T1 Weighted (Wtd.) MRIFig 2.1A: Axial Flair MRIFig 2.1C: Post-Contrast Axial T1 Wtd. MRI Fig 2.1D: Post Contrast Coronal T1 Wtd. MRIFig.

Advertisements

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC randomised trial From.

Supplementary Table S1. Patient demographics of the RRBS discovery set. Characteristics RRBS discovery set TotalIDH1/2 WT IDH1 MUT No. of Patients

Brain Tumors Mark Browning, M.D. IUSME. Differential Diagnosis includes: Primary CNS tumor Most common primary sites of brain mets: – Lung – Breast.

Marker SFRP1 SFRP2 SFRP5 DKK3 WIF1 APC CDH1 Unmethylated Methylated A

Astrocytomas Stud. Francesca Ochea, Carol Davila University of Medicine and Pharmacy Coord. assoc. prof. dr. Ligia Tataranu, Bagdasar-Arseni Emergency.

Volume 155, Issue 3, Pages (March 1996)

Fig. 3. Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival rates according to ADCmeanvalues among the total subjects (A) and among the.

UK Renal Registry 10th Annual Report 2007

INCIDENCE AND SURVIVAL OF CENTRAL NERVOUS SYSTEM MALIGNANCIES ACCORDING TO HISTOLOGICAL SUBTYPES. RESULTS OF A POPULATION-BASED STUDY IN GIRONA (SPAIN)

Oncol Res Treat 2016;39: DOI: /

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Figure 4 Progression-free survival, according to treatment group

Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Molecular subgroups of glioblastoma,

WT G>A G>C G>T (n = 93) (n = 21) (n = 10) (n = 51)

Focus on central nervous system neoplasia

Volume 66, Issue 2, Pages (August 2014)

Masui_suppl Fig1 TMab-6 sc-7215 (0.5 μg/mL) (1.0 μg/mL) Case: Astro_2

Volume 61, Issue 5, Pages (May 2012)

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy Deepa Rangachari, MD, Xiuning.

Volume 148, Issue 1, Pages (January 2018)

by Michael F. Leahy, and J. Harvey Turner

Volume 64, Issue 4, Pages (October 2013)

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

Table 2. Progression-Free Survival

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Treatment of Locally Advanced Pancreatic Cancer

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Resection of Intraabdominal Tumors With Cavoatrial Extension Using Deep Hypothermic Circulatory Arrest Christopher Lau, MD, Padraic O’Malley, MD, Mario.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Practical Radiation Oncology

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

Overall survival by SCT versus observation in first complete remission

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

CNS tumors PhD Tomasz Wiśniewski.

Supplementary Figure S1

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Neuropathology at Southmead

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma Julianna K. Bronk, Nandita Guha-Thakurta,

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Fig. 2. One case of recurrence out of 12 adult patients with totally resected ependymomas without anaplastic pathology or postoperative adjuvant treatment.

Fig. 2. Histology of gliosarcoma is shown

Role of Positron Emission Tomography/Computed Tomography Findings for Adjuvant Chemotherapy Indications in Stage T1b-2aN0M0 Lung Adenocarcinoma Shinsuke.

Fig. 1. Kaplan-Meier curves for PFS and OS

Fig. 3. Survival rates according to histologic diagnosis

Fig. 3. Demonstration of planning of surgical approach via preoperative DTI. Coronal MRI (A) and DTI (B) show left thalamic tumor with anteromedially displaced.

European Urology Oncology

Fig. 5. Serial follow-up sellar MRIs after treatment

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Fig. 2. HR estimated by the multivariate analysis for predicting factors associated with longer overall survival using a Cox regression model at the time.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Levels of neutrophil infiltration into gliomas correlate with tumor grades and tumor progression. Levels of neutrophil infiltration into gliomas correlate.

MRI Atlas of IDH-Wildtype Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes A 3D atlas of glioblastoma location was.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant therapy (C and F). PFS, progression-free survival; OS, overall survival; GTR, gross total resection; STR, subtotal resection; PA, partial resection; GBL, glioblastoma, IDH-wildtype; AA, anaplastic astrocytoma, IDH-wildtype; DMG, diffuse midline glioma, H3 K27M-mutant; CNS, central nervous system; PA, pilocytic astrocytoma. Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant therapy (C and F). PFS, progression-free survival; OS, overall survival; GTR, gross total resection; STR, subtotal resection; PA, partial resection; GBL, glioblastoma,… Brain Tumor Res Treat. 2018 Oct;6(2):60-67. https://doi.org/10.14791/btrt.2018.6.e14